SCHEMBL5739741

SCHEMBL5739741

CCc1c[nH]c2c(NC(=O)CCCl)cc(C(=O)OC)cc12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.39
▸ KDM4E B2RXH2 4/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ HPGD P15428 3/20 0.39
▸ MTNR1A P48039 5/20 0.39
▸ MTNR1B P49286 5/20 0.39
▸ GPR84 Q9NQS5 1/20 0.37
▸ MAPT P10636 4/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ L3MBTL1 Q9Y468 4/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ POLB P06746 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ HTT P42858 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5739672 0.91 MTNR1A (0.38) ALDH1A1KDM4EHSD17B10HPGDMTNR1A
SCHEMBL5220072 0.84 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10HPGDMTNR1A
SCHEMBL5741361 0.79 HPGD (0.43) ALDH1A1KDM4EHSD17B10HPGDMTNR1A
SCHEMBL5806920 0.77 FTO (0.51) ALDH1A1KDM4EHSD17B10HPGDMTNR1A
SCHEMBL5741843 0.75 GPR84 (0.43) ALDH1A1KDM4EHSD17B10HPGDMTNR1A
SCHEMBL5217389 0.74 ALDH1A1 (0.42) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL27648375 0.74 HPGD (0.39) ALDH1A1KDM4EHSD17B10HPGDMTNR1A
SCHEMBL5740289 0.74 KDM4E (0.38) ALDH1A1KDM4EHSD17B10HPGDMTNR1A
SCHEMBL27648377 0.73 KDM4E (0.34) ALDH1A1KDM4EHSD17B10HPGDGPR84
SCHEMBL5305638 0.72 KDM4E (0.40) ALDH1A1KDM4ENPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060229302-A1 Tricyclic indole derivatives and their use in the treatment of alzheimer's disease GLAXO GROUP LIMITED (GB) 2006-10-12 — — US disclosed
CN-1809573-A Tricyclic indole derivatives and their use in the treatment of alzheimer's disease GLAXO GROUP LTD (GB) 2006-07-26 — — CN disclosed
EP-1620438-A1 TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LIMITED (GB) 2006-02-01 — — EP disclosed
WO-2004094430-A1 TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE GLAXO GROUP LIMITED (GB) 2004-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229302-A1 Tricyclic indole derivatives and their use in the treatment of alzheimer's disease BACE2, BACE1, PSEN2 ALDH1A1 3673/4885KDM4E 2053/4885HSD17B10 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback